Dana-Farber Cancer Institute: Central Nervous System Neoplasms trials

The registry lists 11 Central Nervous System Neoplasms studies with Dana-Farber Cancer Institute as lead sponsor. 1 are open to participants now and 4 have results posted.

Phase 1 2Phase 2 7No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS TumorsNot yet recruitingNCT07793994Not applicable
• Preventative Skin Care for Children Undergoing Targeted CNS Tumor TherapyCompletedNCT04479514Phase 2Results posted
• Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive CancerCompletedNCT00357500Phase 2Results posted
• Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or NeuroblastomaCompletedNCT00098865Phase 2Results posted
• Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RTCompletedNCT00084838Phase 2Results posted
• A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) TumorsTerminatedNCT00633958Phase 1
• A-protein Levels in Adult and Pediatric Brain Tumor PatientsCompletedNCT00165542
• Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain TumorCompletedNCT00069940Phase 1
• Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00047294Phase 2
• Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant GliomaCompletedNCT00047281Phase 2
• High-dose ICE With AmifostineCompletedNCT00003657Phase 2